BioCentury
ARTICLE | Company News

Boehringer launches open-access preclinical platform

December 1, 2017 9:50 PM UTC

Boehringer Ingelheim GmbH (Ingelheim, Germany) launched a platform to provide researchers worldwide with open, free access to select molecules in the preclinical stage.

The platform, opn.ME, comprises 19 compounds that Boehringer has deemed suitable for preclinical in vivo proof-of-concept studies. The compounds target a diverse set of proteins implicated in a range of indications, including B cell CLL lymphoma 6 (BCL6); CC chemokine receptor 1 (CCR1; CD191); spleen tyrosine kinase (SYK); fatty acid synthase (FASN; FAS); HCV proteins; and others...